Mammography, the current standard for breast cancer screening, has reduced sensitivity in women with dense breast tissue, contributing to missed or delayed diagnoses. Thermalytix, an AI-based thermal imaging modality, captures functional vascular and metabolic cues that may complement mammographic structural data. This study investigates whether a breast density-informed multi-modal AI framework can improve cancer detection by dynamically selecting the appropriate imaging modality based on breast tissue composition. A total of 324 women underwent both mammography and thermal imaging. Mammography images were analyzed using a multi-view deep learning model, while Thermalytix assessed thermal images through vascular and thermal radiomics. The proposed framework utilized Mammography AI for fatty breasts and Thermalytix AI for dense breasts, optimizing predictions based on tissue type. This multi-modal AI framework achieved a sensitivity of 94.55% (95% CI: 88.54-100) and specificity of 79.93% (95% CI: 75.14-84.71), outperforming standalone mammography AI (sensitivity 81.82%, specificity 86.25%) and Thermalytix AI (sensitivity 92.73%, specificity 75.46%). Importantly, the sensitivity of Mammography dropped significantly in dense breasts (67.86%) versus fatty breasts (96.30%), whereas Thermalytix AI maintained high and consistent sensitivity in both (92.59% and 92.86%, respectively). This demonstrates that a density-informed multi-modal AI framework can overcome key limitations of unimodal screening and deliver high performance across diverse breast compositions. The proposed framework is interpretable, low-cost, and easily deployable, offering a practical path to improving breast cancer screening outcomes in both high-resource and resource-limited settings.

Self-supervised learning (SSL) has transformed vision encoder training in general domains but remains underutilized in medical imaging due to limited data and domain specific biases. We present MammoDINO, a novel SSL framework for mammography, pretrained on 1.4 million mammographic images. To capture clinically meaningful features, we introduce a breast tissue aware data augmentation sampler for both image-level and patch-level supervision and a cross-slice contrastive learning objective that leverages 3D digital breast tomosynthesis (DBT) structure into 2D pretraining. MammoDINO achieves state-of-the-art performance on multiple breast cancer screening tasks and generalizes well across five benchmark datasets. It offers a scalable, annotation-free foundation for multipurpose computer-aided diagnosis (CAD) tools for mammogram, helping reduce radiologists' workload and improve diagnostic efficiency in breast cancer screening.

As early detection of breast cancer strongly favors successful therapeutic outcomes, there is major commercial interest in optimizing breast cancer screening. However, current risk prediction models achieve modest performance and do not incorporate digital breast tomosynthesis (DBT) imaging, which was FDA-approved for breast cancer screening in 2011. To address this unmet need, we present a deep learning (DL)-based framework capable of forecasting an individual patient's 5-year breast cancer risk directly from screening DBT. Using an unparalleled dataset of 161,753 DBT examinations from 50,590 patients, we trained a risk predictor based on features extracted using the Meta AI DINOv2 image encoder, combined with a cumulative hazard layer, to assess a patient's likelihood of developing breast cancer over five years. On a held-out test set, our best-performing model achieved an AUROC of 0.80 on predictions within 5 years. These findings reveal the high potential of DBT-based DL approaches to complement traditional risk assessment tools, and serve as a promising basis for additional investigation to validate and enhance our work.

Mammogram visual question answering (VQA) integrates image interpretation with clinical reasoning and has potential to support breast cancer screening. We systematically evaluated the GPT-5 family and GPT-4o model on four public mammography datasets (EMBED, InBreast, CMMD, CBIS-DDSM) for BI-RADS assessment, abnormality detection, and malignancy classification tasks. GPT-5 consistently was the best performing model but lagged behind both human experts and domain-specific fine-tuned models. On EMBED, GPT-5 achieved the highest scores among GPT variants in density (56.8%), distortion (52.5%), mass (64.5%), calcification (63.5%), and malignancy (52.8%) classification. On InBreast, it attained 36.9% BI-RADS accuracy, 45.9% abnormality detection, and 35.0% malignancy classification. On CMMD, GPT-5 reached 32.3% abnormality detection and 55.0% malignancy accuracy. On CBIS-DDSM, it achieved 69.3% BI-RADS accuracy, 66.0% abnormality detection, and 58.2% malignancy accuracy. Compared with human expert estimations, GPT-5 exhibited lower sensitivity (63.5%) and specificity (52.3%). While GPT-5 exhibits promising capabilities for screening tasks, its performance remains insufficient for high-stakes clinical imaging applications without targeted domain adaptation and optimization. However, the tremendous improvements in performance from GPT-4o to GPT-5 show a promising trend in the potential for general large language models (LLMs) to assist with mammography VQA tasks.

Foundational models have emerged as powerful tools for addressing various tasks in clinical settings. However, their potential development to breast ultrasound analysis remains untapped. In this paper, we present BUSGen, the first foundational generative model specifically designed for breast ultrasound image analysis. Pretrained on over 3.5 million breast ultrasound images, BUSGen has acquired extensive knowledge of breast structures, pathological features, and clinical variations. With few-shot adaptation, BUSGen can generate repositories of realistic and informative task-specific data, facilitating the development of models for a wide range of downstream tasks. Extensive experiments highlight BUSGen's exceptional adaptability, significantly exceeding real-data-trained foundational models in breast cancer screening, diagnosis, and prognosis. In breast cancer early diagnosis, our approach outperformed all board-certified radiologists (n=9), achieving an average sensitivity improvement of 16.5% (P-value<0.0001). Additionally, we characterized the scaling effect of using generated data which was as effective as the collected real-world data for training diagnostic models. Moreover, extensive experiments demonstrated that our approach improved the generalization ability of downstream models. Importantly, BUSGen protected patient privacy by enabling fully de-identified data sharing, making progress forward in secure medical data utilization. An online demo of BUSGen is available at https://aibus.bio.

Breast cancer has long posed a significant threat to women's health, making early screening crucial for mitigating its impact. However, mammography, the preferred method for early screening, faces limitations such as the burden of double reading by radiologists, challenges in widespread adoption in remote and underdeveloped areas, and obstacles in intelligent early screening development due to data constraints. To address these challenges, we propose a weakly supervised multi-view mammography early screening model for breast cancer based on context clustering. Context clustering, a feature extraction structure that is neither CNN nor transformer, combined with multi-view learning for information complementation, presents a promising approach. The weak supervision design specifically addresses data limitations. Our model achieves state-of-the-art performance with fewer parameters on two public datasets, with an AUC of 0.828 on the Vindr-Mammo dataset and 0.805 on the CBIS-DDSM dataset. Our model shows potential in reducing the burden on doctors and increasing the feasibility of breast cancer screening for women in underdeveloped regions.

High rates of false positive test results may be keeping women from sticking to recommended mammogram screenings for breast cancer, a new study has found. Researchers from UC Davis Comprehensive Cancer Center in Sacramento, California, reviewed more than 3.5 million screening mammograms performed among more than one million women between 2005 and 2017. Women who received a true-negative result were more likely to return for future screenings, with a 77% compliance rate. THESE 17 CANCER TYPES ARE MORE COMMON IN GEN X AND MILLENNIALS, AS STUDY NOTES'ALARMING TREND' By comparison, among those who received a false positive, only 61% returned for another mammogram in six months, and 67% returned for a recommended biopsy. The women, who ranged in age from 40 to 73, had not previously received a breast cancer diagnosis.

Full Field Digital Mammograms (FFDMs) and Digital Breast Tomosynthesis (DBT) are the two most widely used imaging modalities for breast cancer screening. Although DBT has increased cancer detection compared to FFDM, its widespread adoption in clinical practice has been slowed by increased interpretation times and a perceived decrease in the conspicuity of specific lesion types. Specifically, the non-inferiority of DBT for microcalcifications remains under debate. Due to concerns about the decrease in visual acuity, combined DBT-FFDM acquisitions remain popular, leading to overall increased exam times and radiation dosage. Enabling DBT to provide diagnostic information present in both FFDM and DBT would reduce reliance on FFDM, resulting in a reduction in both quantities. We propose a machine learning methodology that learns high-level representations leveraging the complementary diagnostic signal from both DBT and FFDM. Experiments on a large-scale data set validate our claims and show that our representations enable more accurate breast lesion detection than any DBT- or FFDM-based model.

Breast cancer screening, primarily conducted through mammography, is often supplemented with ultrasound for women with dense breast tissue. However, existing deep learning models analyze each modality independently, missing opportunities to integrate information across imaging modalities and time. In this study, we present Multi-modal Transformer (MMT), a neural network that utilizes mammography and ultrasound synergistically, to identify patients who currently have cancer and estimate the risk of future cancer for patients who are currently cancer-free. MMT aggregates multi-modal data through self-attention and tracks temporal tissue changes by comparing current exams to prior imaging. Trained on 1.3 million exams, MMT achieves an AUROC of 0.943 in detecting existing cancers, surpassing strong uni-modal baselines. For 5-year risk prediction, MMT attains an AUROC of 0.826, outperforming prior mammography-based risk models. Our research highlights the value of multi-modal and longitudinal imaging in cancer diagnosis and risk stratification.

Doctors believe Artificial Intelligence is now saving lives after a major advancement in breast cancer screenings. In some cases, AI is detecting early signs of the disease years before doctors would find the cancer on a traditional scan. Boca Raton, FL – Some doctors believe artificial intelligence is saving lives after a major advancement in breast cancer screenings. In some cases, AI is detecting early signs of the disease years before the tumor would be visible on a traditional scan. The Christine E. Lynn Women's Health and Wellness Institute at the Boca Raton Regional Hospital found a 23% increase in cancer cases since implementing AI during breast cancer screenings.